Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk teams with Cellartis AB and Lund University Stem Cell Centre

Novo Nordisk teams with Cellartis AB and Lund University Stem Cell Centre

27th October 2008

Novo Nordisk has teamed up with Cellartis AB and Lund University Stem Cell Centre for a collaborative research agreement, it has emerged.

The project is focused on developing insulin-producing cells using human stem cells, with the eventual aim being a cell therapy for insulin-dependent diabetes and, in the long-term, a cure for the condition.

Novo Nordisk said the collaboration intends to discover new knowledge related to how stem cells can be programmed and turned into beta cells able to produce insulin.

Moreover, the company maintained that a cure for diabetes is part of its “vision”.

“[The] agreement is an important first step in achieving our goal of developing a cure for type 1 diabetes,” said Peter Kurtzhals, senior vice-president for diabetes research at Novo Nordisk.”

He added: “The collaboration brings together a highly talented team in stem cell research, which provides an excellent building block to develop potential treatments.”

Cellartis AB currently offers human cardiomyocytes mesenchymal progenitors which are derived from human embryonic stem cells, antibodies and tools. It was founded in 2001.

The Lund Centre was established in 2003 and is one of six Swedish facilities for excellence in life sciences.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.